# reload+after+2024-01-20 18:45:53.630667
address1§Yalelaan 60
city§Utrecht
zip§3584 CM
country§Netherlands
phone§31 630 00 30 35
website§https://www.lavatherapeutics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
fullTimeEmployees§69
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Stephen Allen Hurly M.B.A., M.Sc.', 'age': 55, 'title': 'CEO, President & Executive Director', 'yearBorn': 1968, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Fred M. Powell CPA', 'age': 62, 'title': 'Chief Financial Officer', 'yearBorn': 1961, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Hans  van der Vliet M.D., Ph.D.', 'age': 49, 'title': 'Chief Scientific Officer', 'yearBorn': 1974, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Amy  Garabedian J.D.', 'age': 47, 'title': 'General Counsel & Corporate Secretary', 'yearBorn': 1976, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Wouter van Hunnik', 'title': 'VP & Head of Human Resources', 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Ton  Adang Ph.D.', 'age': 62, 'title': 'Chief Development Officer', 'yearBorn': 1961, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Charles Q. Morris M.D., MBChB, MRCP (UK), Ph.D.', 'age': 58, 'title': 'Chief Medical Officer', 'yearBorn': 1965, 'exercisedValue': 0, 'unexercisedValue': 0}]
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.127
priceToSalesTrailing12Months§5.225307
currency§USD
dateShortInterest§1702598400
forwardEps§-1.79
exchange§NMS
quoteType§EQUITY
shortName§LAVA Therapeutics N.V.
longName§LAVA Therapeutics N.V.
firstTradeDateEpochUtc§1616765400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§f272303e-4305-36b0-b7df-26c82acd7c44
gmtOffSetMilliseconds§-18000000
targetHighPrice§11.0
targetLowPrice§5.0
targetMeanPrice§6.8
targetMedianPrice§6.0
recommendationMean§1.4
recommendationKey§strong_buy
numberOfAnalystOpinions§5
quickRatio§5.108
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
